Selected research
Industry Research
Minimally Invasive Treatment of Lung Cancer Industry Research Report 2026
Market perspective
The global Minimally Invasive Treatment of Lung Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Minimally Invasive Treatment of Lung Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Minimally Invasive Treatment of Lung Cancer market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Minimally Invasive Treatment of Lung Cancer market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Minimally Invasive Treatment of Lung Cancer include Medtronic, LungCare, Broncus, Boston Scientific, Olympus, VISON Medical, Smith and Nephew, Nanjing MICRO-TECH and Intuitive Surgica, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Minimally Invasive Treatment of Lung Cancer market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Minimally Invasive Treatment of Lung Cancer.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Minimally Invasive Treatment of Lung Cancer Market by Company
Medtronic
LungCare
Broncus
Boston Scientific
Olympus
VISON Medical
Smith and Nephew
Nanjing MICRO-TECH
Intuitive Surgica
Auris Health
Angiodynamics
Minimally Invasive Treatment of Lung Cancer Segment by Type
Lung Tumor Ablation
Lung Tumor Embolization
Minimally Invasive Treatment of Lung Cancer Segment by Application
Hospitals
Ambulatory Surgical Centers
Minimally Invasive Treatment of Lung Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Minimally Invasive Treatment of Lung Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Minimally Invasive Treatment of Lung Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Minimally Invasive Treatment of Lung Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Minimally Invasive Treatment of Lung Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lung Tumor Ablation
- Lung Tumor Embolization
Applications
- Hospitals
- Ambulatory Surgical Centers
Companies covered
- Medtronic
- LungCare
- Broncus
- Boston Scientific
- Olympus
- VISON Medical
- Smith and Nephew
- Nanjing MICRO-TECH
- Intuitive Surgica
- Auris Health
- Angiodynamics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Minimally Invasive Treatment of Lung Cancer by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Lung Tumor Ablation
- 2.2.3 Lung Tumor Embolization
- 2.3 Minimally Invasive Treatment of Lung Cancer by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Ambulatory Surgical Centers
- 2.4 Assumptions and Limitations
3 Minimally Invasive Treatment of Lung Cancer Breakdown Data by Type
- 3.1 Global Minimally Invasive Treatment of Lung Cancer Historic Market Size by Type (2021-2026)
- 3.2 Global Minimally Invasive Treatment of Lung Cancer Forecasted Market Size by Type (2027-2032)
4 Minimally Invasive Treatment of Lung Cancer Breakdown Data by Application
- 4.1 Global Minimally Invasive Treatment of Lung Cancer Historic Market Size by Application (2021-2026)
- 4.2 Global Minimally Invasive Treatment of Lung Cancer Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Minimally Invasive Treatment of Lung Cancer Market Perspective (2021-2032)
- 5.2 Global Minimally Invasive Treatment of Lung Cancer Growth Trends by Region
- 5.2.1 Global Minimally Invasive Treatment of Lung Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Minimally Invasive Treatment of Lung Cancer Historic Market Size by Region (2021-2026)
- 5.2.3 Minimally Invasive Treatment of Lung Cancer Forecasted Market Size by Region (2027-2032)
- 5.3 Minimally Invasive Treatment of Lung Cancer Market Dynamics
- 5.3.1 Minimally Invasive Treatment of Lung Cancer Industry Trends
- 5.3.2 Minimally Invasive Treatment of Lung Cancer Market Drivers
- 5.3.3 Minimally Invasive Treatment of Lung Cancer Market Challenges
- 5.3.4 Minimally Invasive Treatment of Lung Cancer Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Minimally Invasive Treatment of Lung Cancer Players by Revenue
- 6.1.1 Global Top Minimally Invasive Treatment of Lung Cancer Players by Revenue (2021-2026)
- 6.1.2 Global Minimally Invasive Treatment of Lung Cancer Revenue Market Share by Players (2021-2026)
- 6.2 Global Minimally Invasive Treatment of Lung Cancer Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Minimally Invasive Treatment of Lung Cancer Head Office and Area Served
- 6.4 Global Minimally Invasive Treatment of Lung Cancer Players, Product Type & Application
- 6.5 Global Minimally Invasive Treatment of Lung Cancer Manufacturers Established Date
- 6.6 Global Minimally Invasive Treatment of Lung Cancer Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032)
- 7.2 North America Minimally Invasive Treatment of Lung Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Minimally Invasive Treatment of Lung Cancer Market Size by Country (2021-2026)
- 7.4 North America Minimally Invasive Treatment of Lung Cancer Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032)
- 8.2 Europe Minimally Invasive Treatment of Lung Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Minimally Invasive Treatment of Lung Cancer Market Size by Country (2021-2026)
- 8.4 Europe Minimally Invasive Treatment of Lung Cancer Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032)
- 9.2 Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Minimally Invasive Treatment of Lung Cancer Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032)
- 10.2 South America Minimally Invasive Treatment of Lung Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Minimally Invasive Treatment of Lung Cancer Market Size by Country (2021-2026)
- 10.4 South America Minimally Invasive Treatment of Lung Cancer Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032)
- 11.2 Middle East & Africa Minimally Invasive Treatment of Lung Cancer Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Minimally Invasive Treatment of Lung Cancer Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Minimally Invasive Treatment of Lung Cancer Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Medtronic
- 12.1.1 Medtronic Company Information
- 12.1.2 Medtronic Business Overview
- 12.1.3 Medtronic Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.1.4 Medtronic Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.1.5 Medtronic Recent Developments
- 12.2 LungCare
- 12.2.1 LungCare Company Information
- 12.2.2 LungCare Business Overview
- 12.2.3 LungCare Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.2.4 LungCare Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.2.5 LungCare Recent Developments
- 12.3 Broncus
- 12.3.1 Broncus Company Information
- 12.3.2 Broncus Business Overview
- 12.3.3 Broncus Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.3.4 Broncus Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.3.5 Broncus Recent Developments
- 12.4 Boston Scientific
- 12.4.1 Boston Scientific Company Information
- 12.4.2 Boston Scientific Business Overview
- 12.4.3 Boston Scientific Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.4.4 Boston Scientific Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.4.5 Boston Scientific Recent Developments
- 12.5 Olympus
- 12.5.1 Olympus Company Information
- 12.5.2 Olympus Business Overview
- 12.5.3 Olympus Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.5.4 Olympus Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.5.5 Olympus Recent Developments
- 12.6 VISON Medical
- 12.6.1 VISON Medical Company Information
- 12.6.2 VISON Medical Business Overview
- 12.6.3 VISON Medical Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.6.4 VISON Medical Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.6.5 VISON Medical Recent Developments
- 12.7 Smith and Nephew
- 12.7.1 Smith and Nephew Company Information
- 12.7.2 Smith and Nephew Business Overview
- 12.7.3 Smith and Nephew Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.7.4 Smith and Nephew Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.7.5 Smith and Nephew Recent Developments
- 12.8 Nanjing MICRO-TECH
- 12.8.1 Nanjing MICRO-TECH Company Information
- 12.8.2 Nanjing MICRO-TECH Business Overview
- 12.8.3 Nanjing MICRO-TECH Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.8.4 Nanjing MICRO-TECH Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.8.5 Nanjing MICRO-TECH Recent Developments
- 12.9 Intuitive Surgica
- 12.9.1 Intuitive Surgica Company Information
- 12.9.2 Intuitive Surgica Business Overview
- 12.9.3 Intuitive Surgica Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.9.4 Intuitive Surgica Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.9.5 Intuitive Surgica Recent Developments
- 12.10 Auris Health
- 12.10.1 Auris Health Company Information
- 12.10.2 Auris Health Business Overview
- 12.10.3 Auris Health Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.10.4 Auris Health Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.10.5 Auris Health Recent Developments
- 12.11 Angiodynamics
- 12.11.1 Angiodynamics Company Information
- 12.11.2 Angiodynamics Business Overview
- 12.11.3 Angiodynamics Revenue in Minimally Invasive Treatment of Lung Cancer Business (2021-2026)
- 12.11.4 Angiodynamics Minimally Invasive Treatment of Lung Cancer Product Portfolio
- 12.11.5 Angiodynamics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst